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ABSTRACT  
Current treatments for metastatic uveal melanoma (mUM) are limited and rarely prolong patient 
survival.  Immunotherapy trials for mUM are few, and to-date have demonstrated only marginal 
success.  High densities of tumour-associated-macrophages (TAMs) and infiltrating T-lymphocytes 
(TILs) in primary UM are associated with poor prognosis.  Little is known about the immune 
microenvironment of mUM.  Our aim was to examine the presence and distribution of TAMs and 
TILs in mUM within the liver.  Whole tissue-sections of liver mUM (n=35) were examined by 
immunohistochemistry.  For TAMs, monoclonal-antibodies (mAbs) against CD68 and CD163 were 
used.  Macrophage density and morphology were scored using previous established systems.  
Density and spatial-distribution of TILs were highlighted using Abs against CD3 (pan-lymphocyte 
marker), CD4 (T-helper cells) and CD8 (T-cytotoxic cells).  CD68+ and CD163+ TAMs were seen 
within the tumour in all 35 specimens; their density was ‘moderate’ in 50% of cases, ‘few’ in 43% 
and the majority showed an ‘indeterminate’ phenotype.  CD3+ TILs were noted both within mUMs 
and surrounding the tumour.  Of these CD8+ TILs were ‘few’ in number within mUM but were 
predominantly seen peri-tumourally at the tumour/normal liver interface, whilst CD4+ TILs showed 
a high perivascular density within mUM.  CD68+ and CD163+ TAMs of ‘indeterminate’ 
morphology were observed in mUM, suggesting a tendency towards the pro-tumourigenic M2-
phenotype.  CD4+ TILs were seen within the mUM, whereas CD8+ TILs tended to be peri-
tumoural.  The biological and functional roles of inflammatory cells in mUM requires further 
investigation, to determine if they represent potential targets for future therapies in mUM. 
 
Keywords: Metastatic uveal melanoma, inflammation, macrophages, T-cells, liver, 
immunotherapy. 
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INTRODUCTION 
Uveal melanoma (UM) is an aggressive intraocular malignancy with up to 50% of UM patients 
developing metastatic disease, usually involving the liver, even several years after the primary 
treatment [1-4].  Current treatments for metastatic UM (mUM) to the liver include: metastectomy, 
liver resection, radio- and/or chemotherapy, radiofrequency ablation; all of these therapies are 
limited, only being suitable for certain patients, and rarely prolonging patient survival [3-6].  
Consequently, there is an urgent need to improve current treatments for established metastatic 
disease alongside adjuvant therapy.   
 
Chronic inflammation is recognized as a hallmark of cancer, and is thought to be a key mediator in 
all steps of tumourigenesis – from initiation, through to progression and metastasis [7-11].  This has 
recently led to the development of new treatment strategies using immunotherapies, such as: 
ipilimumab, nivolumab and pembrolizumab, which have been successful in subsets of patients with 
metastatic cutaneous melanoma.  However, ipilimumab has only shown marginal success in mUM 
to date [4, 12-18]. 
 
It is known that high densities of tumour-associated-macrophages (TAMs) and infiltrating T-
lymphocytes (TILs) in primary UM are found in tumours with a ‘high risk’ of metastasising.  These 
include UM with a large basal diameter, predominantly of epithelioid cell-type, high microvascular 
density, and monosomy 3 [2-4, 19-24].  Macrophages and T-cells are central to the general 
regulation of the immune response.  TAMs have been implicated in tumourigenesis by promoting 
angiogenesis, tumour cell migration and invasion, and tumour growth [7-11, 13-14].  T-cells, in 
contrast, orchestrate the immune response to cancer through recognition, priming and attacking 
cancer cells [25-29].  Very little is known about the immunomodulatory microenvironment of 
mUM, and studying this is difficult as mUM specimens are usually difficult to acquire, and often 
are small percutaneous biopsies.   
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In this study we examined the density and spatial distribution of TAMs and TILs in advanced cases 
of hepatic mUM. 
 
MATERIALS AND METHODS 
The study was approved by the Health Research Authority (REC Ref 11/NW/0759) and conducted 
in accordance with the Declaration of Helsinki.  All samples were provided by the Ocular Oncology 
Biobank (REC Ref 16/NW/0380) and the Liverpool Bio-Innovation Hub following approval from 
their Biobank. 
 
Specimens: Archival formalin-fixed paraffin embedded (FFPE) specimens of mUM were obtained 
from: 1) 19 patients who had undergone local resection of their liver metastases, and 7 patients who 
had percutaneous fine needle biopsies at Aintree University Hospital between 2005 and 2016; and 
2) dissection of the liver metastases during the autopsy of 9 patients (Queen Alexandra Hospital 
Portsmouth).  All of the samples were assessed by a Senior Consultant Histopathologist (SEC), and 
the hepatic metastases classified for the following: staging, dominant cell type, degree of 
pigmentation, presence of necrosis and growth pattern. 
 
Immunohistochemistry (IHC): Sections were cut at 4µm from the FFPE blocks and processed for 
IHC as previously described [30].  Briefly, antigen retrieval and IHC were performed using the 
Dako PT Link and Autostainer Plus with the EnVision™ FLEX+ detection system according to the 
manufacturers’ recommendations (Dako U.K. Ltd., Cambridgeshire, U.K.).   
 
Primary antibodies (Abs) against CD68 (mouse anti-human PG-M1, M0876; Dako, Cambridge, 
U.K.) at 1:200 and CD163 (mouse anti-human, NCL-L-CD163; Leica Biosystems, Newcastle Upon 
Tyne, U.K.) at 1:400 were used to identify the macrophages.  Immunostaining of T-cells was 
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undertaken using the following primary Abs: pan T-cell marker CD3 (polyclonal rabbit anti-human, 
ready to use, IR503; Dako, Cambridge, U.K.); helper T-cell marker CD4 (monoclonal mouse anti-
human, NCL-L-CD4-368; Leica Biosystems, Newcastle Upon Tyne, U.K.) at 1:20 and cytotoxic T-
cell marker CD8 (monoclonal mouse anti-human, M7103; Dako, Cambridge, U.K.) at 1:200.  
Positive and negative controls for each of the primary antibodies were run for each assay. 
 
Positive staining was detected with either: 3-amino-9-ethylcarbazole (AEC peroxidase substrate, 
SK-4200; Vector® Laboratories Ltd., Peterborough, U.K. for 30 minutes) or 3,3’-diaminobenzidine 
(DAB+ chromogen, K3467; Dako, Cambridge, U.K. for 20 minutes).  Slides were counterstained 
with Mayer’s haematoxylin and mounted with an aqueous or resin-based mountant, respectively.     
 
Scoring of TAMs and TILs within the liver metastases:  Following the grading system 
previously described by Mäkitie et al.[22]  TAM and TIL density was qualitatively scored as ‘few,’ 
‘moderate’ or ‘many.’  For TAMs, their morphology was also assessed and the predominant cell 
type was recorded as: ‘round,’ ‘dendritic,’ or as ‘indeterminate’ (in between the dendritic and round 
morphologies).    
 
Slides were subsequently scored by 3 independent observers (YK, CM and HK) and the number, 
spatial distribution and/or morphology was recorded for TAMs and TILs within the liver 
metastases.  The entire specimen was evaluated using a high power field (x40).  Immunopositive 
cells in areas of necrosis or normal liver tissue distant from the mUM were not included in the 
scoring.  Discrepancies in scoring were resolved by consensus between all members involved 
during re-analysis. 
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RESULTS 
Patients and samples: Detailed clinical, pathological and genetic data for liver metastases cases 1 
to 7 have been previously published by our group [30].  The growth patterns of mUM to the liver 
from sections obtained post-mortem (cases 8 to 16) have also been described [31].  For the current 
study, these 16 specimens from both studies and an additional 19 mUM specimens (cases 17 to 35) 
were examined for their inflammatory cell infiltrates.  A total of 35 hepatic metastases were thus 
included. 
 
There were 17 males and 14 females (the gender of 4 autopsy cases was unrecorded).  Age at 
primary management was available for 26/35 cases (Table 1), with a median of 60.5 years (range: 
38 – 78 years).  All patients had died from advanced and widespread mUM.  All but 1 case had 
stage 3 metastases as previously reported [32].  Histological examination showed the liver 
metastases to be of epithelioid cell type in 28 cases and spindle cell type in 7; with an infiltrative 
growth pattern in 21 cases and a nodular growth pattern in 14.  Degree of pigmentation ranged 
from: heavy in 6 cases; moderate in 11; mild in 6 and none in 12 cases.  Fourteen out of the 35 
cases had areas of necrosis (Table 1).   
 
Scoring of TAMs and TILs within the liver metastases: The mean interobserver agreement was 
88% for scoring the number/density of TAMs and TILs, and 85% for evaluating the TAM 
morphology.  Density of TAMs and TILs within the mUMs was scored as shown by the 
representative panels in Fig. 1.  TAM morphology was assessed as shown in Fig. 2.   
 
For TAMs, CD68+ cell infiltrates were scored as ‘moderate’ in 18 cases (51%) and ‘few’ in 13 
cases (37%).  CD163+ cell infiltrates were evaluated as ‘moderate’ in 17 cases (49%) and ‘few’ in 
17 cases (49%) (Table 2).  TAMs of ‘indeterminate’ phenotype dominated in 16/35 (46%) mUM; 
13 cases (37%) showed a ‘dendritic’ phenotype; 5 cases (14%) had equal numbers of both ‘round’ 
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and ‘dendritic’ morphologies (i.e. neither cell morphology dominated); and 1/35 (3%) demonstrated 
a ‘round’ phenotype.  Interestingly, ‘many’ dendritic macrophages were observed at the interface of 
normal liver and tumour tissue.  These were not, however, included in the scoring. 
 
For TILs, CD3+ lymphocyte infiltrates scored as ‘moderate’ in 12 samples (34%), ‘and ‘few’ in 22 
cases (63%) (Table 2).  Diffuse scattered CD3+ cells were noted within the metastases (Fig. 3), 
with ‘many’ also observed at the normal/tumour interface, for all 35 cases.  CD4+ cells were seen 
in all cases (Fig. 3) with evident peri-portal and perivascular aggregations (Fig. 4A).  Densities 
were evaluated as ‘moderate’ in 4 specimens (11%) and ‘few’ in 31 cases (89%).  For CD8+ cells, 
the densities were scored as ‘moderate’ in 6 samples (17%) and ‘few’ in 29 cases (83%) (Table 2).  
Interestingly, aggregates or heavy CD8+ cell infiltrates were observed circumferentially at the edge 
of the tumour (Fig. 4A); whereas only ‘few’ CD8+ cells were seen within the liver metastases in 
most metastases.  In the cases scored as ‘moderate,’ these aggregates of circumferential CD8+ cells 
were noted as present within tumours in multiple areas, and hence included in the scoring. 
 
In some cases, isolated and single mUM cells were observed distant from the main metastatic 
deposit: these were rarely associated with an inflammatory response (Fig. 4B). 
 
DISCUSSION 
In this study we present novel data describing the inflammatory cell infiltrates within and 
surrounding hepatic mUM. Both CD68+ and CD163+ TAMs of an ‘indeterminate’ morphology 
were the dominant subtype in all mUM, although a significant number of cases were also associated 
with macrophages of ‘dendritic’ phenotype. CD4+ TILs were seen in a perivascular distribution 
within the mUM, whereas CD8+ lymphocytes were mainly peri-tumoural with only occasional cells 
seen within the metastatic tumour masses.  
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Macrophages and T-cells are central regulators of inflammation and the immune response [8-11].  
Inflammation is a hallmark of cancer and thought to be a key mediator in all steps of 
tumourigenesis and tumour spread [7-11].  Under the influence of various chemokines and 
cytokines, circulating monocytes and tissue resident macrophages polarise to either the: a) round, 
classically activated, pro-inflammatory, tumour lytic M1 phenotype; or b) the elongated dendritic, 
alternative pathway, pro-angiogenic and pro-tumourigenic M2 TAM phenotype [25, 27, 29, 33-34].  
There is much controversy in the literature regarding the classification of M1 and M2 TAMs, since 
they were first described in the mouse, and it is difficult to determine how much can be extrapolated 
to human macrophage subtypes.  Indeed, the classification of TAMs and their markers is far more 
complex with their further overlapping subcategories and associated plasticity.  That being said, it is 
generally agreed that that CD68+ CD163- macrophages with round morphology represent the M1 
phenotype, and dendritiform CD68+ CD163+ cells correspond to M2 [23-29, 33-37]. High densities 
of M2 TAMs are associated with a poor prognosis in various primary cancers, including cutaneous 
melanomas, ovarian-, pancreatic-, breast-, and colorectal carcinomas, and indeed primary UM [33-
37]. 
In the present study both CD68+ and CD163+ TAMs were seen at similar densities in all hepatic 
mUM samples analysed, suggesting that at least three quarters of macrophages within mUM were 
of the M2 subtype.  These CD68+ CD163+ TAMs were predominantly of an ‘indeterminate’ and 
‘dendritic’ morphology; and were mainly seen within the metastatic tumour masses.  This was also 
reported by Mäkitie et al. in primary UM [22].  The dendritic and indeterminate/intermediate TAM 
morphology further indicates polarisation to a M2 subtype/intermediary.  It remains unknown, 
however, whether these TAMs are hepatic resident macrophages (i.e. the Kupffer cells) entrapped 
within the mUMs, or inflammatory macrophages that have responded to stimuli, or possibly 
macrophages that ‘accompanied’ UM cells during the process of entire metastasis.  Macrophage 
labelling studies in preclinical models are required to answer these questions.    
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Importantly, we also provide novel information regarding the density and distribution of T-cells in 
advanced mUM.  Only a ‘few’ CD4+ T-cells were present within the mUMs, although numerous 
perivascular aggregates were noted. In contrast, CD8+ cytotoxic/killer T-cells predominantly 
encircled the entire metastatic deposit.  This would suggest that CD4+ T-cells and, in particular, 
CD8+ cells are not able to infiltrate the tumour mass, and thus the mUM cells are ‘protected’ from 
immune attack.  Such ‘immune evasion/exclusion,’ has been reported in other solid primary cancers 
[9-11, 35-36].  The ability of cancers to evade immune recognition may be explained by a number 
of factors, including: a) their genetic instability giving rise to certain tumour cells with poor 
immunogenicity with loss of major histocompatibility complex glycoproteins; b) the overexpression 
of oncogene-coded proteins; or c) alteration in the processing of antigenic peptides.  These factors 
would prevent effective immunosurveillance/recognition of the tumour antigens by T-cells, and 
consequently loss of priming of an immune response by the helper T-cells (CD4+) and immune 
attack by cytotoxic T-cells (CD8+) [9-11, 35-36].  The failure of these two critical immune 
functions: direct priming of an immune response and T-cell mediated cytotoxicity, may in part 
explain the successful colonisation process of mUM.  Interestingly, we also observed isolated mUM 
cells scattered within the parenchyma with no associated inflammatory response, in some cases 
quite distant from the larger metastatic deposits.  It is unclear whether these isolated cells have 
seeded from the main hepatic metastases or represent single isolated mUM within a larger pool of 
disseminated tumour cells from the primary UM. 
 
The authors recognise that these are preliminary observations of the advanced metastatic 
environment in a fairly limited number of rare mUM specimens.  Further descriptive studies in a 
much larger cohort including less advanced/early staged cases of mUM (though these may be 
difficult to detect with current imaging modalities), as well as functional studies, are required to 
fully define the role of inflammation in mUM.  Furthermore, we are aware that the CD4+ 
immunostaining may also have highlighted some of the liver’s resident stern Kupffer cells in 
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addition to T-cells.  However, in this regard, caution was taken in the assessment of all specimens 
by the 3 independent observers and any discrepancies were resolved by collaborative consensus. 
Finally, the authors are aware that functional analyses of the macrophages within the mUM would 
be able to determine the degree of their activation and whether there is an active suppression of 
their function by the tumour cells. 
 
By better understanding of the mUM microenvironment and inflammatory cell infiltrates, 
innovative and effective adjuvant immunotherapies against metastatic disease may be identified to: 
augment the anti-tumour T-cell mechanisms perhaps in combination with immune checkpoint 
targeted therapies [9-12, 15, 38], increase immune infiltration or increase/switch polarisation of 
TAMs from the M2-type to the pro-inflammatory, anti-tumourigenic M1 phenotype.  Future 
collaborative studies will also examine inhibitory immune checkpoints, such as: cytotoxic T-
lymphocyte antigen-4 (CTLA4), programmed cell death protein-1 (PD-1) and its ligand (PD-L1). 
 
In summary, we have shown CD68+ CD163+ macrophages of an ‘indeterminate’ and ‘dendritic’ 
morphology in advanced mUM, suggesting tendency towards the pro-tumourigenic M2 phenotype.  
Furthermore, CD4+ TILs were noted in a perivascular distribution within the mUM whereas CD8+ 
TILs were mainly peri-tumoural with only ‘few’ actually infiltrating the tumour.  Further studies 
into the early stages of mUM, are required to better understand the association of inflammatory cell 
infiltrates with mUM cells, and if they represent potential targets for adjuvant immunotherapies. 
 
Acknowledgements: We would like to thank Professor Ian Cree, Professor of Pathology at 
University Hospital of Coventry and Warwickshire, for kindly providing the post mortem liver 
specimens.  We also convey our thanks to Mr Simon Biddolph, Consultant Biomedical Scientist, 
and Mrs Patricia Gerard, Research Technician, for histological specimen preparation.  This work 
AC
CE
PT
ED
 M
AN
US
CR
IP
T
ACCEPTED MANUSCRIPT
11 
 
was funded by the Eye Tumour Research Fund, Charitable Funds, Royal Liverpool University 
Hospital NHS Trust. 
 
Author Contribution: Each author made substantial contributions to the design, acquisition, 
analysis and interpretation of data for the work in this study.  Each author also made substantial 
contribution in: drafting; revising and approval of the final version of the manuscript to be 
published.  
AC
CE
PT
ED
 M
AN
US
CR
IP
T
ACCEPTED MANUSCRIPT
12 
 
REFERENCES 
[1] Kujala E, Mäkitie T, Kivelä T. Very long-term prognosis of patients with malignant uveal 
melanoma. Invest Ophthalmol Vis Sci. 2003; 44: 4651-9. 
[2] Damato B, Dopierala J, Klaasen A, van Dijk M, Sibbring J, Coupland SE. Multiplex ligation-
dependent probe amplification of uveal melanoma: correlation with metastatic death. Invest 
Ophthalmol Vis Sci. 2009; 50: 3048-55.  
[3] Damato B. Progress in the management of patients with uveal melanoma. The 2012 Ashton 
Lecture. Eye 2012; 26: 1157-72.  
[4] Kaliki S, Shields CL, Shields JA. Uveal melanoma: estimating prognosis. Indian J 
Ophthalmol. 2015; 63: 93-102.  
[5] Sato T. Locoregional management of hepatic metastasis from primary uveal melanoma. 
Semin Oncol. 2010; 37: 127-38.  
[6] Gomez D, Wetherill C, Cheong J, et al. The Liverpool uveal melanoma liver metastases 
pathway: outcome following liver resection. J Surg Oncol. 2014; 109: 542-7. 
[7] Hanahan D, Weinberg RA. The hallmarks of cancer. Cell. 2000; 100: 57-70. 
[8] Colotta F, Allavena P, Sica A, Garlanda C, Mantovani A. Cancer-related inflammation, the 
seventh hallmark of cancer: links to genetic instability. Carcinogenesis 2009; 30: 1073-81.  
[9] Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell 2011; 144: 646-74.  
[10] Cavallo F, De Giovanni C, Nanni P, Forni G, Lollini PL. 2011: the immune hallmarks of 
cancer. Cancer Immunol Immunother. 2011; 60: 319-26.  
[11] Chen DS, Mellman I. Oncology meets immunology: the cancer-immunity cycle. Immunity 
2013; 39: 1-10.  
[12] Chattopadhyay C, Kim DW, Gombos DS, et al. Uveal melanoma: From diagnosis to treatment 
and the science in between. Cancer 2016; 122: 2299-312. 
[13] Bronkhorst IH, Jager MJ. Uveal melanoma: the inflammatory microenvironment. J Innate 
Immun. 2012; 4: 454-62.  
AC
CE
PT
ED
 M
AN
US
CR
IP
T
ACCEPTED MANUSCRIPT
13 
 
[14] Bronkhorst IH, Jager MJ. Inflammation in uveal melanoma. Eye 2013; 27: 217-23. 
[15] Carvajal RD, Schwartz GK, Tezel T, Marr B, Francis JH, Nathan PD. Metastatic disease 
from uveal melanoma: treatment options and future prospects. Br J Ophthalmol. 2017; 101: 38-44. 
[16] van den Bosch T, Kilic E, Paridaens D, de Klein A. Genetics of uveal melanoma and cutaneous 
melanoma: two of a kind? Dermatol Res Pract. 2010; 2010: 1-13. 
[17] Robert C, Schachter J, Long GV, et al.; KEYNOTE-006 investigators. Pembrolizumab versus 
Ipilimumab in Advanced Melanoma. N Engl J Med. 2015; 372: 2521-32.  
[18] Rothermel LD, Sabesan AC, Stephens DJ, et al. Identification of an immunogenic subset of 
metastatic uveal melanoma. Clin Cancer Res. 2016; 22: 2237-49 
[19] Scholes AG, Damato BE, Nunn J, Hiscott P, Grierson I, Field JK. Monosomy 3 in uveal 
melanoma: correlation with clinical and histologic predictors of survival. Invest Ophthalmol Vis Sci 
2003; 44: 1008-11. 
[20] Damato BE, Heimann H, Kalirai H, Coupland SE. Age, survival predictors, and metastatic 
death in patients with choroidal melanoma: tentative evidence of a therapeutic effect on survival.  
JAMA Ophthalmol 2014; 132: 605-13. 
[21] Damato BE, Coupland SE. Translating uveal melanoma cytogenetics into clinical care. Arch 
Ophthalmol 2009; 127: 423-9. 
[22] Mäkitie T, Summanen P, Tarkkanen A, Kivelä T. Tumor-infiltrating macrophages (CD68+ 
cells) and prognosis in malignant uveal melanoma. Invest Ophthalmol Vis Sci. 2001; 42: 1414-21. 
[23] Bronkhorst IH, Ly LV, Jordanova ES, et al. Detection of M2-macrophages in uveal 
melanoma and relation with survival. Invest Ophthalmol Vis Sci. 2011; 52: 643-50.  
[24] Herwig MC, Grossniklaus HE. Role of macrophages in uveal melanoma. Expert Rev 
Ophthalmol. 2011; 6: 405-407. 
[25] Mosser DM, Edwards JP. Exploring the full spectrum of macrophage activation. Nat Rev 
Immunol. 2008; 8: 958-69. 
AC
CE
PT
ED
 M
AN
US
CR
IP
T
ACCEPTED MANUSCRIPT
14 
 
[26] Wang H, Chen L. Tumor microenviroment and hepatocellular carcinoma metastasis. J 
Gastroenterol Hepatol. 2013; 28 Suppl 1: 43-8. 
[27] Galdiero MR, Bonavita E, Barajon I, Garlanda C, Mantovani A, Jaillon S. Tumor associated 
macrophages and neutrophils in cancer. Immunobiology. 2013; 218: 1402-10. 
[28] Herwig MC, Holz FG, Loeffler KU. Distribution and presumed proliferation 
of macrophages in inflammatory diseases of the ocular adnexae. Curr Eye Res. 2015; 40: 604-10. 
[29] Ostuni R, Kratochvill F, Murray PJ, Natoli G. Macrophages and cancer: from mechanisms to 
therapeutic implications. Trends Immunol. 2015; 36: 229-39. 
[30] McCarthy C, Kalirai H, Lake SL, Dodson A, Damato BE, Coupland SE. Insights into genetic 
alterations of liver metastases from uveal melanoma. Pigment Cell Melanoma Res. 2016; 29: 60-7. 
[31] Grossniklaus HE, Zhang Q, You S, McCarthy C, Heegaard S, Coupland SE. Metastatic ocular 
melanoma to the liver exhibits infiltrative and nodular growth patterns. Hum Pathol. 2016; 57: 165-
175. 
[32] Grossniklaus HE. Progression of ocular melanoma metastasis to the liver: the 2012 
Zimmerman lecture. JAMA Ophthalmol. 2013; 131: 462-9. 
[33] Leavy O. Macrophages: The shape of things to come. Nat Rev Immunol. 2013; 13: 775. 
[34] McWhorter FY, Wang T, Nguyen P, Chung T, Liu WF. Modulation of macrophage phenotype 
by cell shape. Proc Natl Acad Sci U S A. 2013; 110: 17253-8. 
[35] Hegde PS, Karanikas V, Evers S. The when, the where and the how of immune monitoring for 
cancer immunotherapies in the era of immune checkpoint inhibition. Clin Canc Res 2016; 22: 1865-
74. 
[36] Hiraoka K, Miyamoto M, Cho Y, et al. Concurrent infiltration by CD8+ T cells and CD4+ T 
cells is a favourable prognostic factor in non-small-cell lung carcinoma. Br J Cancer. 2006; 94: 275-
80. 
[37] Cui YL, Li HK, Zhou HY, Zhang T, Li Q. Correlations of tumor-associated macrophage 
subtypes with liver metastases of colorectal cancer. Asian Pac J Cancer Prev. 2013; 14: 1003-7. 
AC
CE
PT
ED
 M
AN
US
CR
IP
T
ACCEPTED MANUSCRIPT
15 
 
[38] Ilie M, Hofman V, Dietel M, Soria JC, Hofman P. Assessment of the PD-L1 status by 
immunohistochemistry: challenges and perspectives for therapeutic strategies in lung cancer 
patients. Virchows Arch. 2016; 468: 511-25. 
 
AC
CE
PT
ED
 M
AN
US
CR
IP
T
ACCEPTED MANUSCRIPT
16 
 
Figure Legends: 
 
Fig. 1: Scoring system developed for assessing the density of TAMs and TILs within hepatic mUM 
(3-amino-9-ethylcarbazole [AEC peroxidase substrate]; magnification x40). 
 
Fig. 2: The morphological types of TAMs (indicated by arrows; AEC peroxidase substrate; 
magnification x40).  A) Dendritic; B) Round. 
 
Fig. 3: TILs density within the hepatic mUM (3,3’-diaminobenzidine [DAB]; magnification x40). 
 
Fig. 4: A) The spatial distribution of TILs within the hepatic metastases (DAB).  Aggregates of 
CD4+ T-cells (indicated by black arrow) were seen in a perivascular distribution, whereas CD8+ T-
cells (indicated by black arrow) were seen at the interface of tumour (T) and normal liver (N). 
B) Isolated distant mUM cells (indicated by black arrow) observed with no surrounding 
inflammatory cell infiltrate (H&E and corresponding Melan A; magnification x20). 
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Table 1: Clinical and histopathological data from the 35 cases of mUM analysed. 
Case No. Gender Age at 
PM 
Sample type Stage* Dominant cell 
type 
Degree of 
Pigmentation 
Necrosis Growth pattern 
(nodular/infiltrative) 
1 M 64 Resection 3 Epithelioid None N Infiltrative 
2 F 39 Resection 2 Epithelioid Mild N Nodular 
3 F 69 Resection 3 Epithelioid None Y Infiltrative 
4 F 64 Resection 3 Epithelioid Mild Y Infiltrative 
5 M 66 Resection 3 Epithelioid None Y Nodular 
6 M 54 Resection 3 Spindle Moderate Y Infiltrative 
7 M 67 Resection 3 Epithelioid None Y Infiltrative 
8 M 75 Autopsy 3 Epithelioid Moderate Y Nodular 
9 M NR Autopsy 3 Epithelioid Moderate N Infiltrative 
10 F NR Autopsy 3 Epithelioid Heavy N Infiltrative 
11 M NR Autopsy 3 Epithelioid Moderate N Infiltrative 
12 F 62 Autopsy 3 Epithelioid Mild Y Infiltrative 
13 M 64 Autopsy 3 Epithelioid Heavy N Infiltrative 
14 F NR Autopsy 3 Spindle Moderate Y Nodular 
15 M 66 Autopsy 3 Epithelioid Moderate Y Infiltrative 
16 M NR Autopsy 3 Spindle Focal heavy Y Infiltrative 
17 M 63 Resection 3 Epithelioid Mild N Infiltrative 
18 F 57 Resection 3 Epithelioid None N Nodular 
19 F 56 Resection 3 Spindle Moderate Y Nodular 
20 F 38 Resection 3 Epithelioid None Y Nodular 
21 NR NR Resection 3 Epithelioid None N Nodular 
22 NR NR Resection 3 Epithelioid Heavy N Infiltrative 
23 NR NR Resection 3 Epithelioid None N Infiltrative 
24 M 45 Resection 3 Epithelioid Heavy N Infiltrative 
25 F 54 Resection 3 Spindle Moderate N Infiltrative 
26 F 53 Resection 3 Epithelioid Mild N Nodular 
27 M 46 Resection 3 Spindle None N Nodular 
28 M 39 Resection 3 Spindle None N Nodular 
29 F 78 Biopsy 3 Epithelioid Mild N Nodular 
30 NR NR Biopsy 3 Epithelioid Moderate N Infiltrative 
31 M 47 Biopsy 3 Epithelioid Moderate N Infiltrative 
AC
CE
PT
ED
 M
AN
US
CR
IP
T
ACCEPTED MANUSCRIPT
22 
 
 
Abbreviations: F = 
female; M = male; PM 
= primary management; 
NR = not recorded; N = no; Y = yes.  *Staging according to Grossniklaus HE [32]. 
32 F 52 Needle biopsy 3 Epithelioid None N Nodular 
33 F 74 Needle biopsy 3 Epithelioid Moderate N Nodular 
34 M 59 Needle biopsy 3 Epithelioid Heavy Y Infiltrative 
35 M 71 Needle biopsy 3 Epithelioid None Y Infiltrative 
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Table 2: Density of TAMs and TILs within the liver metastases of the 35 mUM cases analysed. 
 TAMs TILs 
Case No. CD68+ CD163+ CD3+ CD4+ CD8+ 
1 Moderate  Few  Moderate  Moderate  Moderate  
2 Moderate Few Moderate Few  Moderate 
3 Few Few Few  Few Few  
4 Few  Few Few Moderate Few  
5 Few Few Few Few Few 
6 Few Few Few Few Few 
7 Few Moderate  Moderate Few Few 
8 Moderate Moderate Few Few Few 
9 Moderate Moderate  Moderate Few Few 
10 Moderate Moderate Few Few Few 
11 Few Few Few Few Few 
12 Few Few Few Few Few 
13 Moderate Moderate Few Few Few 
14 Few Few Few Few Few 
15 Few Few Few Moderate Few 
16 Few Few Moderate Moderate Few 
17 Moderate Moderate Moderate Few Moderate 
18 Moderate Moderate oderate Few Few 
19 Many Many Few Few Few 
20 Moderate Few Few Few Few 
21 Many Moderate Moderate Few Moderate 
22 Moderate Moderate Few Few Few 
23 Few Few Few Few Few 
24 Moderate Few Moderate Few Few 
25 Moderate Moderate Few Few Few 
26 Many Moderate Few Few Few 
27 Moderate Few Few Few Few 
28 Few Few Few Few Few 
29 Moderate Moderate Few Few Few 
30 Moderate Moderate Moderate Few Few 
31 Moderate Few Few Few Few 
32 Few Moderate Moderate Few Moderate 
33 Moderate Moderate Moderate Few Few 
34 Moderate Moderate Few Few Few 
35 Many Moderate Many Few Moderate 
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Highlights 
 
 Current treatments for metastatic uveal melanoma (mUM) are limited.   
 
 Little is known about the immune microenvironment of mUM.   
 
 
 M2 tumour-associated-macrophages (TAMs) CD68+ and CD163+ were observed in mUM. 
 
 CD4+ T-lymphocytes (TILs) were seen within mUM; CD8+ TILs were predominantly peri-
tumoural. Functional studies are required. 
 
 TAMs and TILs in mUM may be potential targets for future immunotherapies.  
